Kratom is a plant-derived substance that most people can't easily categorize. It's legal in most U.S. states but banned in others. It acts like a stimulant at low doses and like a mild opioid at higher doses. It's used by people managing chronic pain, by people who got off heroin and stayed off with kratom's help, by people dealing with anxiety, and by people who aren't sure why they started and now find they can't stop.
TL;DR: Kratom (Mitragyna speciosa) is a tree native to Southeast Asia whose leaves contain alkaloids that interact with opioid receptors in the brain — particularly mitragynine and 7-hydroxymitragynine (7-OH). At lower doses it produces stimulant-like effects; at higher doses, opioid-like effects including pain relief, sedation, and mood elevation. Daily use leads to physical dependence. The research is limited but growing. This article covers what kratom is, how it works, why people use it, what the risks are, and what distinguishes standard leaf powder from the high-potency extract products that carry significantly higher risk.
What is kratom?
Kratom is the common name for Mitragyna speciosa, a tropical tree in the coffee family (Rubiaceae) native to Thailand, Malaysia, Indonesia, and Papua New Guinea. The leaves have been used traditionally in Southeast Asia for centuries — chewed fresh by laborers for energy and to manage fatigue, brewed as a tea for pain, and used in cultural and ceremonial contexts.
In the United States, kratom arrived in commercial quantities in the early 2000s and has grown substantially since, primarily through online vendors and specialty stores. The American Kratom Association estimated in 2019 that 10–16 million Americans use kratom. More recent surveys suggest that number has increased, driven partly by the opioid epidemic, chronic pain prevalence, and the limitations of conventional treatment options.
Kratom is not a synthetic drug, a designer drug, or a pharmaceutical. It's a botanical product derived from a plant. Its legal status in the United States is unusual: it remains legal at the federal level (though the FDA has taken enforcement actions against certain products) while being banned in nine states and regulated under the Kratom Consumer Protection Act (KCPA) in fourteen others. That map is shifting in 2026.
How does kratom work in the body?
The two main alkaloids
Kratom leaves contain more than 40 alkaloids, but two are primarily responsible for its psychoactive effects:
| Alkaloid | Concentration in leaf powder | Receptor activity | Primary effects | |----------|-------------------------------|-------------------|-----------------| | Mitragynine | ~66% of alkaloid profile | Partial mu-opioid agonist; kappa and delta opioid agonist; adrenergic activity | Pain relief, mood elevation, stimulant-like effects at low doses | | 7-Hydroxymitragynine (7-OH) | <2% in natural leaf; much higher in extracts | Full mu-opioid receptor agonist; estimated 13× more potent than morphine at the receptor | Stronger opioid-like effects, sedation, higher dependence potential |
The key distinction between these two alkaloids matters practically. In standard leaf powder consumed as traditional tea or capsules, mitragynine dominates and 7-OH is a minor component. In high-potency extracts and "enhanced" products marketed for potency — particularly those specifically advertising 7-OH content — the ratio is artificially concentrated, producing effects and risks closer to a full opioid agonist than to natural leaf kratom.
Per the FDA's 2018 and 2023 analyses, some commercially available kratom extract products contained 7-OH concentrations far exceeding what occurs naturally in Mitragyna speciosa leaf. This is a meaningful safety distinction that the marketing of these products typically obscures.
The dose-response curve
One of the things that makes kratom genuinely unusual is its biphasic dose response. The same substance produces qualitatively different effects at different doses:
-
Low dose (1–5g of leaf powder): Stimulant-like effects — increased energy, alertness, sociability, reduced fatigue. Some people describe it as similar to a strong cup of coffee, or to the early effects of ephedra-based supplements. This is the dose range traditionally used by agricultural workers in Southeast Asia.
-
Higher dose (5–15g of leaf powder): Opioid-like effects become dominant — pain relief, sedation, euphoria, reduced anxiety, slowing of thought and movement. This is the dose range most associated with use for pain management and opioid withdrawal relief in the United States.
-
Very high dose (>15g, or any dose of high-potency extract): Stronger sedation, nausea, risk of vomiting, cognitive impairment, and at sufficient doses, respiratory effects. The risk profile increases significantly at this range, particularly for extract products.
This biphasic quality is why kratom doesn't fit neatly into existing drug categories — it's not quite a stimulant and not quite an opioid, though it has meaningful pharmacological overlap with both.
Is kratom an opiate?
This is one of the most-searched questions about kratom, and the answer matters because the terminology shapes how people understand what they're working with.
Technically, kratom is not an opiate or opioid in the classical sense. The term "opiate" refers to substances derived from the opium poppy (Papaver somniferum), and kratom comes from an entirely different plant family. Pharmacologically, kratom's alkaloids are not opioids by structure.
However: kratom alkaloids act as opioid receptor agonists — they bind to and activate the same receptors (primarily mu-opioid receptors) that morphine, heroin, oxycodone, and buprenorphine bind to. The physiological effects — pain relief, sedation, physical dependence, withdrawal symptoms upon cessation — are opioid-like in character even if the molecular structure is different.
This is why researchers and clinicians typically describe kratom as having "opioid-like properties" or acting as a "partial opioid receptor agonist" rather than as an opioid per se. It's a meaningful distinction in terms of mechanism, and it has clinical implications: kratom withdrawal resembles opioid withdrawal, naloxone has some effectiveness in kratom overdose, and buprenorphine has evidence as a treatment for kratom dependence.
The practical answer: if you're trying to understand why kratom use is producing withdrawal symptoms similar to what you might have experienced with prescription painkillers or heroin, the opioid receptor connection is the explanation.
Why do people use kratom?
The 2020 Johns Hopkins survey (Garcia-Romeu et al. 2020; n=2,798 kratom users) provides the most comprehensive look at why people use kratom in the United States. The findings are worth knowing because they challenge common assumptions about who uses kratom and why.
Opioid withdrawal management and replacement
The most commonly reported reason for kratom use in the Hopkins survey was managing opioid withdrawal or replacing opioid use. Approximately 41% of respondents reported using kratom as an opioid replacement. This is not incidental — kratom's partial mu-opioid agonism makes it pharmacologically capable of reducing opioid withdrawal symptoms, which is why people in opioid withdrawal sometimes turn to it.
This use is controversial: the FDA has taken the position that kratom should not be used as an opioid treatment because it is not approved, not regulated for this purpose, and carries its own dependence risk. Researchers and harm-reduction advocates have noted that for people who cannot access or afford buprenorphine, kratom has in practice functioned as an accessible alternative that has enabled some people to stop using illicit opioids.
This is not a simple story with a clear answer. What it is: a real phenomenon that the Hopkins data documents, and that dismissing kratom users as simply "choosing a different drug" obscures.
Chronic pain management
Pain management was among the most common reasons reported in the Hopkins survey — particularly musculoskeletal pain, back pain, and pain from chronic conditions. A significant subset of kratom users came to it after problems with prescription opioids: either dependency, lack of access, or the unwillingness to continue on a substance with more severe dependence and overdose risk.
Anxiety, depression, and mood regulation
A substantial portion of users in the Hopkins data reported using kratom for anxiety, depression, or general mood regulation. This aligns with kratom's known adrenergic and opioid receptor activity — the combination can produce a calming, mood-elevating effect, particularly at moderate doses.
Energy and focus
At lower doses, kratom produces stimulant-like effects that some people use for productivity, energy, and concentration. This is closer to the traditional Southeast Asian use pattern and is more common among users who use lower, less frequent doses.
Social and recreational use
A minority of users in the Hopkins data reported primarily social or recreational use — a pattern more similar to caffeine use than to opioid use. These users tend to report lower doses and lower rates of physical dependence.
What are the risks?
Physical dependence
Daily use of kratom at moderate to high doses leads to physical dependence — the body adapts to the alkaloids' presence and produces withdrawal symptoms when they're removed. Withdrawal resembles opioid withdrawal: muscle pain, insomnia, anxiety, nausea, restlessness, and strong urges to dose.
Dependence develops on a spectrum. Occasional or low-dose users may not develop significant dependence. Daily high-dose users, particularly those using extract products, typically do.
Physical dependence is not the same as addiction in the clinical sense. Many people use kratom daily and are physically dependent without their use causing significant impairment to their functioning. That said, dependence does mean that stopping produces a predictable withdrawal period, and the withdrawal timeline is a significant practical reality for people trying to stop.
The 7-OH extract problem
The most significant safety concern in the kratom market as of 2026 is not kratom leaf powder but high-potency extract products — particularly those containing concentrated 7-OH.
7-OH has full mu-opioid receptor agonist activity. At high concentrations, it carries respiratory depression risk more similar to classical opioids than to the partial agonism of mitragynine. Several kratom-related deaths have been associated with 7-OH extract products, often in combination with other substances.
The regulatory response has been: FDA import alerts, warning letters to specific manufacturers, and state-level bans that sometimes target all kratom but were often motivated by the extract product risk.
If you're using kratom, the distinction between leaf powder and 7-OH extract products is the single most important safety variable. They are not equivalent products.
Adulteration risk
Some kratom products have been found to contain adulterants — including synthetic opioids, heavy metals from manufacturing contamination, and other compounds not disclosed on the label. This risk is higher with extract products and lower-quality vendors. KCPA-regulated states require testing and labeling that provides some protection; unregulated markets don't.
Kratom and the liver
There are case reports of kratom-associated liver injury (hepatotoxicity) in the medical literature. These appear to be rare and most commonly associated with heavy, long-term use. They do not appear in casual or low-dose users at meaningful frequency, but they represent a documented risk worth knowing.
Drug interactions
Kratom is metabolized by cytochrome P450 enzymes (primarily CYP3A4 and CYP2D6). This means it can interact with other medications metabolized by the same pathways — including some antidepressants, benzodiazepines, and opioids. If you're on prescription medication and using kratom, a conversation with your prescriber about potential interactions is worth having.
Kratom in recovery: what to know
If you've come to this article while working on reducing or stopping kratom use, a few things are worth naming directly.
The function kratom served is real. If you used kratom for pain, opioid withdrawal, anxiety, or work capacity, those needs don't disappear when you stop. Recovery from kratom use includes understanding what kratom was doing — not just stopping it — so that you can find something else that serves those functions without the dependence cycle. That's different from viewing kratom use as a problem without a context.
Leaf powder and extract withdrawal are different. If your kratom use has involved primarily leaf powder, the withdrawal timeline and the taper protocol give you an accurate picture. If you've been using high-potency 7-OH extracts, the process is more complex and clinical support is worth involving.
If your state is banning kratom: Tennessee and Kansas both have bans taking effect July 1, 2026; Michigan's ban took effect in March 2026. If you're in one of these states and dependent on kratom, the forced-cessation playbook covers how to prepare for supply disruption and what to do when it arrives.
There is no single right path. Some people stop kratom entirely. Some taper to a stable low dose. Some use buprenorphine as a bridge. All of those can be legitimate paths, depending on your situation. The goal is to make a decision that fits your actual circumstances — not someone else's idea of what recovery is supposed to look like.
The honest summary
Kratom is a real substance with real pharmacological effects and real risks. It's not as dangerous as high-potency opioids. It's not as benign as its proponents sometimes claim. It has genuine utility for specific purposes, and it produces genuine dependence with daily use.
Understanding it clearly — not through a vendor's marketing, not through an anti-drug PSA, but through the actual research — is the most useful starting point for making informed decisions about it, whatever those decisions turn out to be.
Coach Aria is a digital coaching program for people working on recovery from kratom dependence. It's built around the research on what actually helps — understanding the function the substance served, building the skills and support that replace it, and working through withdrawal and the post-acute period with structure. It runs privately on your phone. If you're at the point where you're researching kratom, you're at the beginning of a process — this is here when you're ready to go further.